Pivotal Life Sciences — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Plexiumplexium.cominJul 2025SEC filingmedium confidence
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoMichael Martin(President, Chief Executive Officer)
BoardMike Grey(Executive Chairman)in
Board seatRob Hopfner· per SEC Form D · $60.1M raise · filed Aug 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.